Cencora, Inc.
Close on Oct 19, 2026
- Market cap
- $65.94B
- P/E (TTM)
- 25.2
- Dividend yield
- 0.65%
About Cencora
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Cencora, Inc. sources and distributes brand-name, specialty, and generic pharmaceuticals, over-the-counter medications, and home healthcare supplies for human and animal health. The company also provides commercialization, consulting, packaging, pharmacy automation, and specialty logistics solutions. It operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. Customers include health systems, acute care hospitals, retail and mail-order pharmacies, medical clinics, physician practices, veterinarians, and biopharmaceutical manufacturers.
The company maintains a global presence across the United States, Europe, Canada, and select international markets, supported by a network of distribution centers including a national facility in Columbus, Ohio. Its workforce exceeds 51,000 employees worldwide, with approximately 41% based in the United States. The company is incorporated in Delaware, and the provided text does not specify the city or state of its headquarters.
Summary of the business section of Cencora's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cencora, Inc.
- Founded
- 2001
- Headquarters
- Conshohocken, PA
- Address
- 1 West First Avenue 19428
- Phone
- (610) 727-7000
- Website
- cencora.com
- Employees
- 51,000, Sep 30, 2025
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- Ernst& YoungLLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- COR
- Exchange
- NYSE
- Shares outstanding
- 191M, Jul 31, 2026
- Public float
- $37.89B, Mar 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 16, 2009; 2-for-1, Dec 29, 2005; 2-for-1, Mar 25, 1999
- SEC CIK
- 1140859
- CUSIP
- 03073E105
- ISIN
- US03073E1055
- LEI
- AI8GXW8LG5WK7E9UD086
- EIN
- 23-3079390
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert P. Mauch | President & CEO, Director | 69,155 |
| Steven H. Collis | Executive Chairman, Director | 305,913 |
| Lazarus Krikorian | SVP & Chief Accounting Officer | 16,169 |
| Elizabeth S. Campbell | Executive Vice President | 19,455 |
| Silvana Battaglia | Executive Vice President | 23,624 |
| Eva C. Boratto | Chief Financial Officer | 3 |
| James F. Cleary | Chief Financial Officer | 160,363 |
| Pawan Verma | EVP, Chief Data & Info Officer | 5,148 |
| Lon R. Greenberg | Director | 17,128 |
| Lauren M. Tyler | Director | 4,456 |
| Ellen Cooper | Director | 893 |
| Dennis M. Nally | Director | 13,188 |
| Dermot Mark Durcan | Director | 31,767 |
| Lorence H. Kim | Director | 4,249 |
| Lori Ryerkerk | Director | 1,073 |
| Redonda Miller | Director | 3,751 |
| Werner Baumann | Director | 3,687 |
| Frank Clyburn | Director | 1,724 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Robert P. Mauch | $18.26M | $33.89M | $6.11M | $342 | $144 |
| FY2024 Robert P. Mauch | $18.48M | $61.40M | $7.81M | $244 | $156 |
| FY2023 Robert P. Mauch | $17.51M | $33.84M | $5.09M | $193 | $128 |
| FY2022 Robert P. Mauch | $16.74M | $26.07M | $4.45M | $144 | $118 |
| FY2021 Robert P. Mauch | $14.87M | $39.79M | $4.60M | $125 | $123 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had more than 51,000 employees globally, of which approximately 47,000 were full-time employees and approximately 41% were U.S.-based employees.”
Corporate history
Events identified from SEC filings